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them. Further evaluation is needed to determine the safety
of long-term use.
GASTROINTESTINAL DISEASES/DISORDERS—
Economics Outcomes Presentations
PGI3
IMPACT OF PROTON PUMP INHIBITOR
UTILIZATION PATTERNS ON
GASTROESOPHAGEAL REFLUX 
DISEASE-RELATED COSTS
Hall JA1, Dodd SL2, Durkin M2, Sloan S2
1Ingenix Pharmaceutical Services, Eden Prairie, MN, USA;
2Janssen Pharmaceutica,Titusville, NJ, USA
OBJECTIVE: To determine proton pump inhibitor (PPI)
treatment patterns and their affect on gastroesophageal
reﬂux disease-related costs.
METHODS: This study used claims data to identify 
continuously enrolled GERD-diagnosed subjects newly
treated with a proton pump inhibitor (PPI) between
October 1, 1999 and March 31, 2000. Data were ana-
lyzed for six months following PPI initiation. Results were
stratiﬁed by ﬁrst PPI ﬁlled during the study period. Com-
pliance (measured by possession ratio), dosage escalation
(>25% of initial dose), and daily average consumption
(DACON) were measured. Subjects were assigned to one
of four GERD severity groups based on ICD-9 diagnosis
codes. Regression analysis was performed on GERD-
related costs using treatment patterns and type of PPI
drug as covariates of interest. Confounders including
GERD severity were controlled for in the analysis.
RESULTS: Of 75,452 subjects, there were 51,232
(67.9%) lansoprazole, 22,829 (30.3%) omeprazole and
1,391 (1.8%) rabeprazole subjects. Possession ratio was
not signiﬁcantly different by drug. Only 3.5% of rabepra-
zole subjects escalated versus 5.5% of omeprazole 
subjects and 9.3% of lansoprazole subjects (p = 0.0001).
Among subjects with esophageal ulcer or hiatal hernia,
rabeprazole users had a signiﬁcantly lower ﬁnal DACON
(1.03) versus both lansoprazole (1.20) and omeprazole
subjects (1.22, p = 0.0299). From the regression models,
subjects who were compliant with therapy (ratio ≥ 0.80)
had 43% higher GERD-related pharmacy costs and 33%
higher GERD-related total costs (both p < 0.001). GERD-
related medical costs were not signiﬁcantly affected by
compliance. Subjects who ﬁlled lansoprazole had 9.4%
higher GERD-related pharmacy costs versus rabeprazole
subjects (p < 0.01). Omeprazole subjects had 12.5%
higher GERD-related total costs versus rabeprazole sub-
jects (p < 0.01), while lansoprazole subjects had 18%
higher GERD-related total costs versus rabeprazole 
subjects (p < .001).
CONCLUSIONS: Rabeprazole subjects had lower
GERD-related costs, less escalation and lower DACON
compared to lansoprazole and omeprazole subjects. Com-
pliance was not signiﬁcantly different between drugs, nor
did it decrease GERD-related costs.
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OBJECTIVES: Recent clinical studies report lower 30-
day rebleeding rates associated with the use of intra-
venous proton pump inhibitors (IV PPIs) for treatment of
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patients with ulcer bleeds exhibiting high risk stigmata at
time of endoscopy. We assessed the cost-effectiveness of
starting an IV infusion of pantoprazole (80-mg bolus 
followed by 8mg/hr for 3 days) for high risk, non-variceal
ulcer lesions after therapeutic endoscopy had been 
performed.
METHODS: A decision analysis was conducted by cre-
ating a decision tree model in Data 3.5. The assumptions
of probabilities and costs were derived from the litera-
ture, a local cost database, and a national Registry of
patients with Upper Gastrointestinal Bleeding undergoing
Endoscopy (RUGBE). Efﬁcacy was the proportion of
patients with an episode of rebleeding. Both threshold
and sensitivity analyses were conducted. The time horizon
was 30 days following hospital admission.
RESULTS: It was estimated that hospitalization costs 
for patients with uncomplicated and complicated ulcer
bleeds were respectively CDN$1546.08 and $3275.63
per patient. Over the range of probabilities covered by
the 95% conﬁdence interval assigned to the rebleeding
rate, the optimal strategy was the use of IV PPI infusion
versus non-use. The IV PPI strategy exhibited higher
effectiveness (17% decrease in rebleeding) at lower cost
($67 less per hospitalized patient). The estimates were
robust across a wide range of clinically relevant variables.
Assumptions about hospitalization costs had the greatest
effect on the decision to start/not start the IV PPI.
CONCLUSIONS: Based on the assumptions of our
model, the most cost-effective approach is to start an IV
PPI infusion for a patient with a high-risk ulcer bleed
having undergone urgent endoscopic therapy.
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EFFECT OF POSTOPERATIVE ILEUS ON
LENGTH OF STAY IN COLECTOMY
Sarawate C, Dalal M
University of Illinois at Chicago, Chicago, IL, USA
Colectomy is a common surgical procedure known to be
associated with Postoperative Ileus (POI). POI leads to
inhibited bowel function following surgical procedures
and it delays discharge of hospital patients by affecting
patient’s tolerance to solid/liquid intake. Thus, POI can
potentially extend length of stay (LOS) and increase 
hospital costs in colectomy patients.
OBJECTIVES: To evaluate impact of POI on LOS and
determine factors that lead to POI in hospital patients
undergoing colectomy.
METHODS: Adult patients who underwent colectomy,
with/without POI were identiﬁed from cross-sectional
1999 National Hospital Discharge Survey (NHDS) using
ICD-9-CM code for surgical procedures and diagnosis
(457.1, 457.4 and 458). Hospital patients with cardiac,
respiratory, or urinary comorbidities were excluded.
Patient characteristics and LOS were compared between
patients with/without POI using student’s t-test. Patient
characteristics affecting development of POI were evalu-
ated using logistic regression. All analyses were conducted
using SAS version 8.0. Data were weighted to obtain
national estimates.
RESULTS: The mean LOS was 13.29 (+/- 8.74) vs. 7.49
(+/- 3.37) days in patients with/ without POI respectively.
The LOS in patients with POI was signiﬁcantly greater
than those without POI (p < 0.0001) after re-scaling
record weights. Patient characteristics of age, gender, race
and primary payer were not signiﬁcantly associated with
development of POI.
CONCLUSIONS: POI leads to signiﬁcant increase in
LOS of patients who underwent colectomy. We suspect
severity of illness and treatment characteristics to inter-
act with POI. However, data on these variables were not
available in the survey. Therefore, we could not detect 
a signiﬁcant association of the factors, considered in 
this study, on POI. Future research would be needed to
ascertain impact of severity of illness and treatment 
characteristics on POI.
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OBJECTIVES: This study investigates the extent to which
IBS imposes a ﬁnancial burden on an employer.
METHODS: Administrative claims data from a national,
Fortune 100 manufacturer that includes all medical, phar-
maceutical, and disability claims for the company’s
employees, spouses, dependents, and retirees (n >
100,000) were used for this analysis. IBS patients (n =
1,610) were identiﬁed using ICD-9-CM codes of individ-
uals aged 18 through 64 years, who received primary
treatment for IBS; or secondary treatment for IBS and
primary treatment for constipation or abdominal pain,
between 1996 and 1998. Over 93% (N = 1,509) of these
IBS patients were matched based on age, sex, zip code,
and employment status to control beneﬁciaries. Excluded
from both the IBS and control samples were patients
treated for malignant neoplasm of digestive organ 
and peritoneum, inﬂammatory bowel disease, Crohn’s
disease, ulcerative colitis, and diverticulitis. Direct
(medical and pharmaceutical) and indirect (disability and
medically-related work absence) costs of IBS patients and
controls were estimated using SAS, version 8.
RESULTS: On average, an IBS patient cost the employer
$1,251 more than an employee not treated for IBS
($4,527 versus $3,276; p < 0.0001). Direct medical costs
accounted for 83% of total costs associated with IBS.
Hospital outpatient costs accounted for the largest
portion; average hospital outpatient costs were $1,258
and $742 for IBS patients and controls, respectively 
(p < 0.0001). The average number of medical claims per
